Antibody Discovery Market Report Scope & Overview:
The antibody discovery market size was valued at USD 8.42 billion in 2024 and is expected to reach USD 17.68 billion by 2032, growing at a CAGR of 9.74% over 2025-2032.
To Get more information on Antibody Discovery Market - Request Free Sample Report
The global antibody discovery market is gaining substantial momentum, primarily due to the increasing requirement for targeted therapies and biologics for the treatment of chronic diseases, such as cancer, infectious diseases, and autoimmune diseases.
In May 2024, AbCellera expanded its platform to enable faster antibody discovery and development with AI-driven tools for better epitope coverage, driver models that leverage AI to enable better epitope targeting, and increased market share of antibody discovery for AI-integrated platforms.
Significant growth in the antibody discovery market can be attributed to the increasing R&D activity in the area of therapeutic antibodies and rising demand for protein therapeutics, technical advances in antibody engineering, maturation of parents of antibody targets, and robust features of antibodies. In 2023, U.S. biopharmaceutical companies' investment in R&D reached more than USD 102 billion, including substantial capital in research to unlock the potential of antibody therapies, according to the Pharmaceutical Research and Manufacturers of America (PhRMA). Furthermore, regulatory recommendations by the FDA and EMA to grant accelerated approval for mAbs and biosimilars are favouring the market.
The U.S. antibody discovery market is driven by the presence of large antibody discovery companies, well-established academic research partnerships, and a large number of clinical studies. The increasing trend toward personalized medicine, as well as the increasing demand for new antibody formats, such as bispecific antibodies and antibody-drug conjugates (ADCs), will drive further growth. In addition, enhanced antibody discovery market research shows improved supply potential with specialized expression systems and CROs providing full-service antibody development.
For instance, the collaboration between AstraZeneca and Absci on generative AI for antibody discovery, in March 2024, also reflects the current antibody discovery market dynamics toward integrating machine learning into early-stage biologic development-contrasting with the increasing corporate investments in creative antibody discovery market trends.
Table: Adoption of Emerging Technologies in Antibody Discovery (2021–2025)
|
Technology |
Description |
Adoption Rate (%) in 2025 |
Key Players Utilizing Technology |
|---|---|---|---|
|
AI-based Antibody Design |
Accelerates epitope prediction |
64% |
AbCellera, Evotec, Twist Bioscience |
|
Single B-Cell Screening |
Enables identification of rare antibodies |
48% |
Berkeley Lights, Creative Biolabs |
|
Phage Display Optimization |
Enhances high-affinity binder selection |
72% |
GenScript, Fairjourney Biologics |
|
Nanodisc Platforms |
Stabilizes membrane proteins for screening |
35% |
BioIntron, private research labs |
|
CRISPR-based Functional Assays |
Speeds up target validation |
28% |
Charles River, Genscript |
Market Dynamics:
Drivers:
Rising Demand for Targeted Therapies and Innovations in Biologics Pipeline Fuel Market Growth
The demand for targeted therapies and precision medicine, backed by continuous biologic drug development, will be the major driver for the antibody discovery market growth. The increasing incidence rate of complex diseases, including cancer, autoimmune disease, and infectious disease, is compelling the biopharmaceutical company to invest largely in monoclonal antibodies and related biologics. Biologics (with antibodies leading) are expected to account for more than 55% of global top 100 drug sales in 2026, as per the Evaluate Pharma report.
The market is buoyed by increased R&D spending (for instance, Roche, Pfizer, and Merck spend upward of USD 12 billion on research each year). More efficient ways to facilitate such animals’ immunity have grown the antibody discovery market analysis with great speed, with new screening technologies, like phage display, single B-cell technologies, and microfluidics, have revolutionized the discovery of antibodies, such that it is extremely fast and specific. Furthermore, other Food and Drug Administration (FDA) accelerated antibody product approvals early in the second quarter will drive increased regulatory support and provide additional incentive to commercial-scale approval (for instance, Talvey and Tepkinly, 2023).
Based on collaboration between biotech start-ups and academia, and rising partnership with CROs and CDMOs, the market is expected to become more attractive across early-stage and late-stage development, due to the continuous supply of antibody discovery solutions.
Restraints:
High Costs, Technical Complexity, and Regulatory Barriers in Development Hamper Market Expansion
Despite potential growth, the antibody discovery market has significant barriers, including high cost and prolonged development time of antibodies. According to the Tufts Center for the Study of Drug Development, on average, it takes 10 to 15 years and costs more than USD 2.6 billion to bring a new biologic drug to market. The technical complexity of antibody selection, validation, and optimization, particularly for bispecific and humanized antibodies, requires significant expertise, infrastructure, and investment. In addition, as strict regulatory requirements are imposed, for instance by the FDA and EMA, a complete preclinical and clinical development data set is required, which in many cases may result in delays and added costs of compliance.
High failure rates in biologic drug development have persisted, particularly in early discovery and clinical phases, because of challenges such as immunogenicity, suboptimal pharmacokinetics, or off-target activities. Supply chain interference for raw materials, including recombinant proteins and cell culture reagents, may also hinder efficient development-staging workflows. Additionally, it can be costly to invest in research and development, particularly if you are a smaller biotech company competing and trying to justify long-term research and development projects. Cumulatively, these factors limit the level of the revenue antibody discovery market share, particularly for emerging players and in high-risk therapeutic segments where the ROI is not guaranteed.
Segmentation Analysis:
By Antibody Type
Monoclonal antibodies were the largest segment of the antibody discovery market in 2024, with a market share of around 68%. Due to their higher specificity, long half-life, and successful initial application in treating complicated diseases, like cancer, rheumatoid arthritis, and infectious diseases, mAb has become a new star in the field of antibody medicine. Their dominance is also being bolstered by multiple FDA approvals and growing biosimilar pipelines. Moreover, polyclonal antibodies are the fastest-growing segment, which is driven by their ability to bind to a variety of epitopes of a single antigen, which is useful in diagnostics, vaccines, and basic research. Their potential for quick and cheap fabrication and wide dissemination in academic and industrial labs has also contributed to their expanded use.
By Service
By service, phage display was the largest segment in 2024, accounting for 47% of the global antibody discovery market. This predominance is due to the capacity of this technology to produce humanized, high-affinity antibodies with fast screening and selection, especially in cancer and autoimmune disease studies. Phage display platforms have been made more efficient by the inclusion of automation and AI in such technology. Conversely, the hybridoma section is the fastest growing, owing its most significant contribution to the generation of monoclonal antibodies, especially in animal models and in vaccine candidate studies. Its relevance remains in the academic and preclinical arena, and therefore development of NMR for early discovery is logical and growing.
By End-User
In 2024, the pharmaceutical and biotech sectors dominated the antibody discovery market, accounting for a 64% share. Their leadership is anchored in R&D investment, expansion of biologics pipelines, and collaborations with CROs and academia. They are highly dependent on antibody discovery platforms for new drug development, with particular emphasis on new cancer and immune treatments. Contrarily, research laboratories are the fastest-growing end-user segment, owing to rising government and institutional funding and custom antibody services. Experimental validation, biomarker studies, and translational research between universities and institutes to driving the growth of this segment.
Table: End-User Investment Trends in Antibody Discovery (2021–2025)
|
End-User Type |
Avg. Annual R&D Spending (USD Bn) |
% Increase Since 2021 |
Key Investment Areas |
|---|---|---|---|
|
Pharmaceutical Companies |
45.3 |
24% |
Monoclonal and bispecific mAbs |
|
Biotechnology Firms |
32.8 |
36% |
Recombinant Antibodies, AI Tools |
|
Academic & Research Labs |
11.4 |
41% |
Custom antibody development |
Regional Analysis:
The largest share of the global antibody discovery market in 2024 was estimated to be North America, due to significant investment in biopharmaceutical R&D, a strong clinical trial infrastructure, and the presence of a large number of leading market players.
The U.S. antibody discovery market size was valued at USD 2.75 billion in 2024 and is expected to reach USD 5.12 billion by 2032, growing at a CAGR of 8.13% over 2025-2032. The U.S. continues to hold the largest share in part because government and private sector support U.S. biopharma R&D spending totaled more than USD 102 billion in 2023, PhRMA found. The US FDA also approved several monoclonal antibody therapies in recent years, driving demand for development. Infrastructure, academic collaborations, and the existence of key players such as Charles River Laboratories and Danaher also boost the strength of the region. In Canada, growth is on the rise based on a greater emphasis on biotech innovation and favorable government grants, and Mexico is slowly moving the needle on its biosimilars and clinical trial support, according to the research. The market in the region is backed by supportive regulations, advanced modes of screening, and the increasing requirement for patient-specific treatments.
The European region is the second-largest market for antibody discovery, with a robust infrastructure to support pharmaceutical manufacturing, a favorable regulatory environment, and an expanding biosimilars pipeline. Germany is the leading country owing to its developed biomanufacturing facilities, large R&D spending, and an established clinical research environment. Germany is host to many leading biotech hubs and public-private partnerships that drive innovation in antibody development. France and the U.K. are also big players, with France investing heavily in immunotherapy and the U.K. in AI-powered discovery platforms. The biggest European market is a “fast-growing” Poland, due to increasing clinical trial activity and foreign investment in biotech. Through the scientific advice and fast approval for biologics in Europe, a more rapid development and commercialization can be achieved in different countries.
The Asia Pacific is the fastest-growing region of the antibody discovery market globally due to a developing biotech industry, increasing healthcare spending, and a burgeoning demand for targeted therapies. China is the clear leader in the region because of big investments in biopharma, government-backed innovation programs, and local players such as WuXi Biologics leading the way on antibody platforms. National biotech investment topped more than USD 30 billion in 2023, according to China’s Ministry of Science and Technology. India, too, is growing at a fast clip, led by government-sponsored efforts such as “Biotech Startup Accelerators” and growing partnerships for CROs. Japan also contributes substantially via innovative technologies and an aligned regulatory framework for approvals of therapeutic antibodies. Growth is being driven by a higher use of Asian CROs for discovery services and by production cost efficiency. Nations such as South Korea and Singapore are playing an increasingly powerful role through innovation hubs and R&D-driven policies, which in turn are driving regional growth.
Table: Strategic Collaborations and Licensing Deals (2023–2025)
|
Year |
Partner Companies |
Deal Type |
Value (USD Million) |
Focus Area |
|---|---|---|---|---|
|
2023 |
AbSci – AstraZeneca |
AI-based Discovery |
247 |
Oncology, Autoimmune |
|
2024 |
Twist Bioscience – Astellas |
Target Discovery |
95 |
Oncology |
|
2025 |
Sanofi – Earendil Labs |
Bispecific Antibodies |
1,720 (milestones) |
Inflammatory Diseases |
|
2025 |
Evotec – Korean Gov’t & Zymedi |
R&D Grant |
4.5 |
Pulmonary Disorders |
Get Customized Report as per Your Business Requirement - Enquiry Now
Key Players:
Leading antibody discovery companies in the market comprise Eurofins Scientific, Evotec, Twist Bioscience, Genscript Technology Corporation, Biocytogen, Sartorius AG, Danaher Corporation, Fairjourney Biologics S.A., Creative Biolabs, and Charles River Laboratories.
Recent Developments:
In April 2025, Sanofi licensed global rights to a pair of bispecific antibody candidates (HXN‑1002, HXN‑1003) from Earendil Labs, paying USD125 million upfront and with the potential of USD1.72 billion in milestones.
In April 2025, Evotec announced substantial progress in its molecular glue collaboration with Bristol Myers Squibb, triggering USD 75 million in performance-based and program-based milestone payments.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 8.42 billion |
| Market Size by 2032 | USD 17.68 billion |
| CAGR | CAGR of 9.74% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Antibody Type (Monoclonal, Polyclonal, and Others) • By Service (Phage Display, Hybridoma, and Others) • By End-user (Pharmaceutical and Biotechnology Companies, Research Laboratories, and Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Eurofins Scientific, Evotec, Twist Bioscience, Genscript Technology Corporation, Biocytogen, Sartorius AG, Danaher Corporation, Fairjourney Biologics S.A., Creative Biolabs, and Charles River Laboratories. |
Ans: Emerging technologies include AI-driven antibody design, single B-cell screening, microfluidics, and nanodisc platforms for membrane protein targeting, enhancing precision and speed in discovery processes.
Ans: The global antibody discovery market is expected to grow at a CAGR of 9.74% over the forecast period from 2025 to 2032, driven by rising biologics demand and oncology research.
Ans: Monoclonal antibody discovery is driving market demand due to its high specificity, therapeutic success in chronic diseases, and expanding applications in cancer, autoimmune, and infectious disease treatments.
Ans: Contract Research Organizations (CROs) support antibody discovery companies by offering end-to-end services, including screening, optimization, and production, enabling faster and cost-effective drug development.
Ans: Collaborations between pharma and biotech firms accelerate innovation in recombinant antibodies, bispecific antibodies, and biosimilars, while expanding the global reach of antibody-based therapeutics.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 R&D Investment and Pipeline Activity (2024)
5.2 Antibody Discovery Projects, by Technology Platform (2024)
5.3 Therapeutic Area Trends (2024)
5.4 Regional Antibody Discovery Initiatives and Funding (2024)
5.5 Strategic Collaborations, Licensing Deals & M&A Activity (2023–2024)
5.6 Time-to-Lead Candidate Identification (Trend Analysis, 2021–2024)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Antibody Discovery Market Segmentation by Antibody Type
7.1 Chapter Overview
7.2 Monoclonal
7.2.1 Monoclonal Market Trends Analysis (2021-2032)
7.2.2 Monoclonal Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Polyclonal
7.3.1 Polyclonal Market Trends Analysis (2021-2032)
7.3.2 Polyclonal Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Others
7.4.1 Others Market Trends Analysis (2021-2032)
7.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Antibody Discovery Market Segmentation By Service
8.1 Chapter Overview
8.2 Phage Display
8.2.1 Phage Display Market Trend Analysis (2021-2032)
8.2.2 Phage Display Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Hybridoma
8.3.1 Hybridoma Market Trends Analysis (2021-2032)
8.3.2 Hybridoma Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Others
8.4.1 Others Market Trends Analysis (2021-2032)
8.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Antibody Discovery Market Segmentation By End-user
9.1 Chapter Overview
9.2 Pharmaceutical and Biotechnology Companies
9.2.1 Pharmaceutical and Biotechnology Companies Market Trends Analysis (2021-2032)
9.2.2 Pharmaceutical and Biotechnology Companies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Research Laboratories
9.3.1 Research Laboratories Market Trends Analysis (2021-2032)
9.3.2 Research Laboratories Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Others
9.4.1 Others Market Trends Analysis (2021-2032)
9.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Antibody Discovery Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.2.3 North America Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.2.4 North America Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.2.5 North America Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.2.6.2 USA Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.2.6.3 USA Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.2.7.2 Canada Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.2.7.3 Canada Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.2.8.2 Mexico Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.2.8.3 Mexico Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.3 Europe
10.3.1 Trends Analysis
10.3.2 Europe Antibody Discovery Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.3 Europe Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.3.4 Europe Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.3.5 Europe Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.3.6 Germany
10.3.1.6.1 Germany Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.3.1.6.2 Germany Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.3.1.6.3 Germany Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.3.7 France
10.3.7.1 France Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.3.7.2 France Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.3.7.3 France Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.3.8 UK
10.3.8.1 UK Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.3.8.2 UK Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.3.8.3 UK Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.3.9 Italy
10.3.9.1 Italy Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.3.9.2 Italy Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.3.9.3 Italy Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.3.10 Spain
10.3.10.1 Spain Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.3.10.2 Spain Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.3.10.3 Spain Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.3.12 Poland
10.3.12.1 Poland Antibody Discovery Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.12.1 Poland Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.3.12.3 Poland Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.3.12.3 Poland Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.3.13 Turkey
10.3.13.1 Turkey Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.3.13.2 Turkey Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.3.13.3 Turkey Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.3.14 Rest of Europe
10.3.14.1 Rest of Europe Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.3.14.2 Rest of Europe Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.3.14.3 Rest of Europe Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.4 Asia-Pacific
10.4.1 Trends Analysis
10.4.2 Asia-Pacific Antibody Discovery Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.4.3 Asia-Pacific Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.4.4 Asia-Pacific Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.4.5 Asia-Pacific Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.4.6.2 China Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.4.6.3 China Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.4.7.2 India Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.4.7.3 India Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.4.8.2 Japan Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.4.8.3 Japan Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.4.9.2 South Korea Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.4.9.3 South Korea Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.4.10 Singapore
10.4.10.1 Singapore Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.4.10.2 Singapore Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.4.10.3 Singapore Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.4.11 Australia
10.4.11.1 Australia Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.4.11.2 Australia Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.4.11.3 Australia Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.4.12 Rest of Asia-Pacific
10.4.12.1 Rest of Asia-Pacific Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.4.12.2 Rest of Asia-Pacific Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.4.12.3 Rest of Asia-Pacific Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Trends Analysis
10.5.2 Middle East and Africa East Antibody Discovery Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.5.3 Middle East and Africa Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.5.4 Middle East and Africa Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.5.5 Middle East and Africa Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.5.6 UAE
10.5.6.1 UAE Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.5.6.2 UAE Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.5.6.3 UAE Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.5.7 Saudi Arabia
10.5.7.1 Saudi Arabia Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.5.7.2 Saudi Arabia Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.5.7.3 Saudi Arabia Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.5.8 Qatar
10.5.8.1 Qatar Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.5.8.2 Qatar Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.5.8.3 Qatar Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.5.9 South Africa
10.5.9 1 South Africa Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.5.9 2 South Africa Antibody Discovery Market Estimates and Forecasts By Service (2021-2032) (USD Billion)
10.5.9 3 South Africa Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.5.10 Rest of Middle East & Africa
10.5.10.1 Rest of Middle East & Africa Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.5.10.2 Rest of Middle East & Africa Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.5.10.3 Rest of Middle East & Africa Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Antibody Discovery Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.6.3 Latin America Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.6.4 Latin America Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.6.5 Latin America Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.6.6.2 Brazil Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.6.6.3 Brazil Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.6.7.2 Argentina Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.6.7.3 Argentina Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Antibody Discovery Market Estimates and Forecasts, by Antibody Type (2021-2032) (USD Billion)
10.6.8.2 Rest of Latin America Antibody Discovery Market Estimates and Forecasts, By Service (2021-2032) (USD Billion)
10.6.8.3 Rest of Latin America Antibody Discovery Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
12. Company Profiles
12.1 Eurofins Scientific
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Products/ Services Offered
12.1.4 SWOT Analysis
12.2 Evotec
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Products/ Services Offered
12.2.4 SWOT Analysis
12.3 Twist Bioscience
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Products/ Services Offered
12.3.4 SWOT Analysis
12.4 Genscript Technology Corporation
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Products/ Services Offered
12.4.4 SWOT Analysis
12.5 Biocytogen
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Products/ Services Offered
12.5.4 SWOT Analysis
12.6 Sartorius AG
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Products/ Services Offered
12.6.4 SWOT Analysis
12.7 Danaher Corporation
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Products/ Services Offered
12.7.4 SWOT Analysis
12.8 Fairjourney Biologics S.A.
12.8.1 Company Overview
12.8.2 Financial
12.8.3 Products/ Services Offered
12.8.4 SWOT Analysis
12.9 Creative Biolabs
12.9.1 Company Overview
12.9.2 Financial
12.9.3 Products/ Services Offered
12.9.4 SWOT Analysis
12.10 Charles River Laboratories
12.10.1 Company Overview
12.10.2 Financial
12.10.3 Products/ Services Offered
12.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Antibody Type
Monoclonal
Polyclonal
Others
By Service
Phage Display
Hybridoma
Others
By End-user
Pharmaceutical and Biotechnology Companies
Research Laboratories
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g., Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players